The downgrades from low-accuracy firms, while cautionary, are not statistically strong. Given consensus bullishness and improving EPS revisions, traders could view weakness toward $700 as a potential buying entry, but should wait for price stability or confirmation from a high-accuracy firm before committing.
REGN drugs
REGN drug pipeline →- ● Otarmeni 3/10 Approved (accelerated approval) · BLA filing 2026
- ▲ Cemdisiran 6/10 Filed/PDUFA (Phase 3 NIMBLE complete; NDA under FDA Priority Review)
- ▲ Dupixent 4/10 Approved (marketed since 2017; additional Phase 3 trials ongoing for label expansion)
- ● Evkeeza 4/10 Approved
- ● EYLEA HD 4/10 Approved
- 12 more · All REGN drugs, catalysts & trials →
How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 18 $629.34entry
- T+1 · 6mo ago +0.07%α +0.72% · $629.76
- T+5 · 6mo ago +0.45%α −1.17% · $632.17
- T+20 · 5mo ago −2.28%α −4.47% · $614.98
- T+60 · 3mo ago +26.80%α +22.22% · $797.99
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
On May 18, 2026, two firms downgraded Regeneron Pharmaceuticals (REGN). Citigroup cut from Buy to Neutral, slashed price target from $900 to $700, nearly in line with the current $698.25. Leerink Partners downgraded from Outperform to Market Perform with a $641 target, implying ~8% downside. Both firms have below-average track records on REGN (Citi 43% accuracy on 7 calls, Leerink 50% on 2 calls). Consensus remains strongly bullish: 30 of 38 analysts (79%) rate Buy or Strong Buy, with a mean price target of $875.31 (25.4% upside). EPS revision momentum is positive, with 15 upgrades vs 6 downgrades for the next quarter. Insider sales are small and routine; institutional activity is mixed (Two Sigma trimming but Norges Bank adding a $1B position). While the cluster downgrade signals near-term caution, the positive consensus and earnings momentum suggest the stock may find support near $700. The low accuracy of the downgrading firms reduces the significance of this action.
Impact Score
Consensus & Targets
Consensus is heavily bullish: 30 of 38 analysts (79%) rate Buy or Strong Buy, 8 Hold (21%), and 0 Sell. The average price target is $875.31 with a median of $882.5. The downgrades are contrarian to the consensus view, which sees 25.4% upside from current levels.
Mean price target $875.31, median $882.5, high $1057, low $730. Current price $698.25 implies 25.4% upside to mean. Citigroup's new $700 PT of $700 is below the consensus low of $730, and Leerink's $641 is even lower. Both new targets are well below the consensus mean of $875.31, reflecting a more pessimistic view than the average analyst.
Recent Analyst Activity
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-05-18 | JP Morgan | maintain | Overweight | $850.00 |
| 2026-05-18 | Piper Sandler | maintain | Overweight | $855.00 |
| 2026-05-18 | Wells Fargo | maintain | Equal-Weight | $700.00 |
| 2026-05-18 | RBC Capital | maintain | Sector Perform | $707.00 |
| 2026-05-18 | Citigroup | downgrade | Neutral | $700.00 |
| 2026-05-18 | Leerink Partners | downgrade | Market Perform | $641.00 |
| 2026-05-01 | Guggenheim | maintain | Buy | $995.00 |
| 2026-04-30 | RBC Capital | maintain | Sector Perform | $762.00 |
| 2026-04-30 | Barclays | maintain | Overweight | $917.00 |
| 2026-04-30 | Truist Securities | maintain | Buy | $796.00 |
In the last 30 days, REGN has seen 0 upgrades and 2 downgrades (these). EPS revisions for the current quarter are positive: 15 upward vs 6 downward in 30 days, with consensus rising $12.30 to $13.09. Full-year EPS also revised up 16 vs 7 down. This positive earnings momentum contrasts with the negative analyst action.
Firm Track Record: Citigroup
Citigroup accuracy: 55% on 4355 calls | avg return: 4.9%
Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 15 firms with ≥5 scored calls.
| Firm | Accuracy | Calls | Avg Return | vs Average |
|---|---|---|---|---|
| UBS | 67% | 4/6 | 5.1% | top tier |
| Canaccord Genuity | 57% | 4/7 | 9.4% | above average |
| TD Cowen | 50% | 1/2 | 3.1% | below average |
| Bernstein | 50% | 1/2 | 6.2% | below average |
| Cantor Fitzgerald | 50% | 4/8 | -4.5% | below average |
| BMO Capital | 50% | 3/6 | -3.7% | below average |
| Morgan Stanley | 50% | 5/10 | 4.1% | below average |
| Goldman Sachs | 50% | 1/2 | -3.6% | below average |
| Leerink Partners | 50% | 1/2 | -23.7% | below average |
| Evercore ISI Group | 50% | 1/2 | -4.9% | below average |
Citigroup has a 43% accuracy rate on 7 REGN calls, with an average return of 3.8%, below the average. Leerink is 50% on 2 calls with a -23.7% average return, the worst among all firms. The best performer is UBS (67% accuracy on 6 calls, +5.1% return); the worst by accuracy is RBC Capital (33% on 18 calls, -8.9%). Both downgrading firms are among the lowest in accuracy on this name.
Earnings Estimates
Next earnings: Jul 30, 2026
| Period | EPS Est. | EPS Range | Revenue | Revisions (7d) |
|---|---|---|---|---|
| 0q | $10.86 | $8.27 to $13.25 | $3.8B | ↑2 ↓0 |
| +1y | $48.20 | $41.10 to $60.05 | $17.6B | ↑2 ↓0 |
| +1q | $13.09 | $9.36 to $17.10 | $4.2B | ↑5 ↓0 |
| 0y | $46.50 | $38.82 to $53.61 | $15.9B | ↑6 ↓0 |
Cross-Platform Signals
Insider sales are small ($10k by CFO Ryan in April/May, $38k by director Zoghbi in February) and likely routine; no informative cluster. Congressional: Rep. Khanna bought $1k‑$15k in April, negligible. Institutional actions are mixed: Two Sigma trimmed 40% and Renaissance near-exited (‑97%), but Norges Bank initiated a $1B market position and Sound Shore added 53%. Short interest is not available. Overall, the downgrade divergence with still‑positive institutional buying and upward EPS revisions, reducing the joint signal reliability of the bearish signal.
Investment Themes
Documents Analyzed
Report based on filing metadata.
Track record
53 reports on REGN
10 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +31.76% at T+20 after the Oct 6, 2026 report. 16 of 20 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $951.23 Now $952.40 +0.12% settles Dec 16
- Nov 16, 2026today 144 Neutral 2/10 Entry $948.00 Now $952.40 +0.46% settles Dec 16
- Nov 12, 20264d ago Press Release Bullish 5/10 Entry $955.47 Now $952.40 −0.32% settles Dec 14
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 5, 202611d ago Insider Cluster Neutral 3/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 4, 202612d ago 144 Neutral 1/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers